AGC Biologics competitors

CEO with 25+ years of experience in health care, biotechnology and pharmaceutical industries:- extensive experience in oncology, endocrinology, CNS, rare disease, ultra-orphan markets- overseen multiple launches in both small and large companies- broad experience in managed care, marketing, field, medical affairs, operations and finance- built and led entire commercial organizations from the ground up- established innovative and strategic commercialization approaches

Wang Yan are a Chief Executive Officer at Cytovance Biologics, President at Scientific Protein Labs Llc, and Board Member at Cytovance Biologics. They have worked as VP:Business Development at Scientific Protein Labs Llc.

Arpit Patel is an Associate Director, Quality Assurance and Compliance at Aurolife Pharma LLC and Chief Executive Officer & Board Member at CorePharma LLC and is based in Dayton, New Jersey. He has worked as Quality Engineer, Quality Compliance at 29 Consulting LLC - Vascular Therapies, Inc; Quality Assurance Consultant at CorePharma LLC; and Acting Director, Quality Assurance and Compliance at Aurolife Pharma LLC. Arpit attended Fairleigh Dickinson University-Metropolitan Campus between 2007 and 2009; Gujarat University, L M College of Pharmacy; and Telnet between 2002 and 2006.

Mr. Tabasso holds a B.A. from Cornell University, and a J.D. from Villanova University. Prior to joining KVK-Tech, Mr. Tabasso spent 16 years in private practice at a large Philadelphia law firm, where his practice focused on commercial litigation, business restructuring, and transactional work. After serving as outside counsel for many years, Mr. Tabasso joined KVK as President and CEO in August, 2013. Since that time, Mr. Tabasso’s focus has been on committing KVK to three core values: Regulatory Compliance, Safety, and Productivity. Mr. Tabasso has also dedicated KVK to strengthening its commitment to our customers and supply chain partners

Sergey Vlasenko is a President and Chief Executive Officer at Prozyme, Inc. and is based in Hayward, California.

J. William Freytag, Ph.D. has served as Chairman of our Board of Directors since January 2011 and has served as a member of our Board of Directors since March 2008. Dr. Freytag served as a member of the Board of Directors of ARCA biopharma, Inc., a publicly-traded biopharmaceutical company, from January 2009 to March 2011, serving as chair and a member of its compensation committee and its Lead Director from January 2009 to March 2011. Dr. Freytag served as a director of Immunicon Corp., a publicly-traded developer of diagnostic products, as well as a member of its compensation committee, from May 1998 until its merger with Veridex, LLC in June 2008. Dr. Freytag was Chairman and Chief Executive Officer of Aspreva Pharmaceuticals Corp., a publicly-traded pharmaceutical company, from July 2007 until its merger with Galenica AG in January 2008. Prior to Aspreva, Dr. Freytag was President, Chief Executive Officer and Chairman of the Board of Directors of Myogen, Inc., a publicly-traded pharmaceutical company, from July 1998 until Myogen was acquired by Gilead Sciences, Inc. in November 2006. From November 2006 through June 2007, Dr. Freytag served as Senior Advisor to Gilead. From October 1994 to May 1998, Dr. Freytag was a Senior Vice President at Somatogen, Inc., a publicly-traded biotechnology company. Prior to Somatogen, he was President of Research and Development at Boehringer Mannheim Corporation, an international healthcare company, from May 1990 to September 1994. Previously, Dr. Freytag spent ten years with DuPont in various research and business positions in the Medical Products Department. Dr. Freytag received a B.S. from Purdue University and a Ph.D. in biochemistry from the University of Kansas Medical Center.

Martin Meeson is a President,Founder and Chief Executive Officer at FUJIFILM Diosynth and President and Chief Executive Officer at FUJIFILM Diosynth Biotechnologies and is based in Morrisville, North Carolina. He attended Newcastle University.